uniQure N.V. - Ordinary Shares (QURE) News
Filter QURE News Items
QURE News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
QURE News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest QURE News From Around the Web
Below are the latest news stories about UNIQURE NV that investors may wish to consider to help them evaluate QURE as an investment opportunity.
Is uniQure N.V. (QURE) Among the Best Growth Stocks to Buy and Hold in 2025?We recently compiled a list of the 12 Best Growth Stocks to Buy and Hold in 2025. In this article, we are going to take a look at where uniQure N.V. (NASDAQ:QURE) stands against the other growth stocks. The Future of Rate Cuts in 2025 The latest data from the job market in the United States […] |
uniQure Announces Pricing of its Public OfferingLEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its underwritten public offering of 4,411,764 of its ordinary shares at a public offering price of $17.00 per share. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by |
uniQure Announces Proposed Public OfferingLEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced an underwritten public offering of its ordinary shares and pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purch |
uniQure price target raised to $32 from $12 at StifelStifel analyst Paul Matteis raised the firm’s price target on uniQure (QURE) to $32 from $12 and keeps a Buy rating on the shares. The firm is “compelled” by the already developing efficacy signal/trends at 24-months where uniQure got alignment with the FDA and continuing RMAT plus CBER tailwinds, which it thinks make the set up “bullish” as uniQure moves towards filing a BLA, the analyst tells investors. Published first on TheFly – the ultimate source for real-time, market-moving breaking finan |
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?Shares of the international gene therapy developer uniQure (NASDAQ: QURE) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's Huntington's disease candidate. During the first 12 days of December, shares of uniQure rocketed 152% higher, and investors want to know if this stock has legs that can propel it further in 2025. |
QURE Soars on FDA Alignment for Speedy Approval of Huntington's DruguniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease. |
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & MoreIt was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news also continued to be in the spotlight. |
UniQure Stock Doubles After Striking A Deal With The FDA For Huntington's DrugUniQure stock doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease treatment. |
UniQure shares soar on chance of speedy approval for Huntington’s therapyThe company now says that, during a recent meeting with the FDA, the two parties agreed on some key elements for an accelerated approval application. |
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington’s Disease~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~ ~ FDA agrees that the composite Unified Huntington’s Disease Rating Scale (cUHDRS) may serve as an intermediate clinical endpoint for Accelerated Approval ~ ~ Conference call today at 8:30 a.m. ET ~ LEXINGTON, Mass. and AMSTERDAM, Dec. 10, 2024 (GLOBE NEWSWIRE) |